Navigation Links
Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug
Date:3/20/2012

gs, many of which have significant side effects. The potential market for XEN-D0103 is significant with one in four adults over the age of 40 developing AF in their lifetimes and approximately three million patients suffering atrial-fibrillation-related strokes each year. We are now preparing for the initiation of phase 2 efficacy trial of XEN-D0103 in patients with atrial fibrillation".

XEN-D0103 is the lead product of Xention's portfolio of atrial fibrillation drugs. In addition to targeting Kv1.5, Xention is also conducting research on inhibition of the acetylcholine-activated potassium channel IKACh (Kir3.1/3.4) and highly potent and selective IKACh antagonists are currently under evaluation in preclinical models. The ion channels Kv1.5 and IKACh represent two of the most exciting targets for novel atrial fibrillation therapies, and Xention is at the forefront in developing effective drug modulators of these channels.

About Atrial Fibrillation:

Atrial Fibrillation (AF) is the most common sustained cardiac rhythm disturbance, occurring in between 1 and 2 per cent of the general population but increasing rapidly with age.  It is estimated that over six million Europeans suffer from this arrhythmia and its prevalence is calculated to increase by at least 2.5 fold in the next 50 years as the population ages.  AF confers a five-fold increased risk of stroke and one in five of all strokes are attributable to AF.  The ischemic strokes seen in association with the arrhythmia are often fatal, and those that survive are often left crippled by their stroke and likely to suffer recurrent strokes.  Around one per cent of the healthcare budget of Western European and North American countries is spent on the management of AF.  Thus this disease presents a rapidly growing social, medical and public health problem in need of urgent solution.

Notes to Editors

About Xention:

Xention Ltd is a leading d
'/>"/>

SOURCE Xention
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GenVec Reports Fourth Quarter and 2011 Year-End Financial Results
2. EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results
3. Phalanx Biotech Group Reports Robust Revenue Growth in 2011
4. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
5. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
6. Gen-Probe Reports Financial Results for the Fourth Quarter of 2011
7. Neuland Labs Reports Third Quarter Fiscal Year 2012 Financial Results
8. Cepheid Reports Fourth Quarter and Full Year 2011 Results
9. Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M
10. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
11. Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... ... recently presented new data on the relationship of genetics and hypertension at the ... on Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts an ...
(Date:8/26/2015)... N.J. , Aug. 26, 2015  Roka Bioscience, ... focused on providing advanced testing solutions for the detection ... CEO will present at the Sidoti & Company Emerging ... conference will be held at the New York Marriott ... presentation will be available through the investor relations section ...
(Date:8/26/2015)... 26, 2015  Platform therapeutic company Symic Biomedical, ... a $1.5M Phase II SBIR grant from the ... its therapeutic agent to reduce arteriovenous fistula (AVF) ... stage renal disease (ESRD) patients undergoing hemodialysis. The ... Diabetes and Digestive and Kidney Diseases (NIDDK), will ...
(Date:8/26/2015)... 26, 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, ... today announced that the Company has been informed that ... wholly owned by Mr. Yuen Kam, chairman of the ... outstanding shares (the "Shares") of  Excellent China Healthcare Investment ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... , Expects to Collaborate on Testing OVAR Effectiveness , ... (NKI) ( www.neuro-kinetics.com ), manufacturers of noninvasive ... vestibular, neurological and other disorders, said today that the ... Otolaryngology,s Vestibular Testing Center has purchased and installed its ...
... SAN DIEGO, June 8 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ... a commitment to purchase shares of convertible preferred stock pursuant ... representing gross proceeds of approximately $2 million. The preferred stock ... option of the investor at a price of $0.1105 per ...
... N.J., June 8 A study in ... , published by Elsevier, demonstrates that the Hepascore(TM) liver ... diagnose and stage liver fibrosis in patients with chronic ... biopsy, the standard of care for staging fibrosis, in ...
Cached Biology Technology:University of Michigan Installs Neuro Kinetics' I-Portal(R) NOTC System 2University of Michigan Installs Neuro Kinetics' I-Portal(R) NOTC System 3ADVENTRX Pharmaceuticals Announces Financing 2ADVENTRX Pharmaceuticals Announces Financing 3Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C 2Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C 3Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C 4
(Date:8/26/2015)... PUNE, India , August 26, 2015 ... (Two, Three, Four, and Five Factor), Application (Travel & ... and Geography - Global Forecast to 2020", published by ... 9.60 Billion by 2020, growing at a CAGR of ... 71 Tables and 82 F igures spread through ...
(Date:8/20/2015)... PLEASANTON, Calif. , Aug. 20, 2015 /PRNewswire/ ... focused on consumers that are active and healthy. ... used in the hospital environment to help improve ... released a video from the Wearable Technologies ... MD discussed new applications for wearables in healthcare.    ...
(Date:8/18/2015)... 2015  Navitas today announced that it ... Submission Content Management webinar scheduled on August ... to the Implementation of Regulatory Submission Standards ... industry, vendors, health authorities, consultants and the ... a standard method of implementing electronic submission ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... In the book Sex Hormones and Immunity to Infection, ... Bloomberg School of Public Health,s W. Harry Feinstone Department ... the immune systems of men and women and how ... Roberts, PhD, offer a fresh perspective for the treatment ...
... French . , With a sum of ... 9, to EPFL professor Michael Graetzel. The jury in Helsinki ... man whose dye-sensitized solar cells that bear his name. ... to the development of dye-sensitized solar cells, the chemist and ...
... soybeans, palm, and other edible oilseed plants as sources for ... mold, that produces and socks away large amounts of oils ... of a study in ACS, bi-monthly journal Energy & ... manufacturers usually produce biodiesel fuel from plant oils such ...
Cached Biology News:JHSPH faculty tackles immune system differences between the sexes 2
Mouse polyclonal antibody to REXO4 - XPMC2 prevents mitotic catastrophe 2 homolog (Xenopus laevis)...
... Stabilizer is an aqueous solution that contains ... chemicals in a PBS buffer (phosphate buffered ... product contains a combination of 0.02% methylisothiazolone ... StabilCoat Plus Stabilizer provides optimum performance for ...
... designed for quick and easy protein purification ... two 0.25mm holes laser cut at the ... remain liquid-tight during incubation of the gel ... protein diffuses from the gel into the ...
... design specifically for western blots ,• Optically ... designed for staining western blots. The reduced ... of the disposable tray requires less dye ... savings to the user. Pour spouts in ...
Biology Products: